2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Wang Jiayu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d. - Her2-negative Metastatic Breast Cancer, Vinorelbine | Phase 2 | Unknown | Wang Jiayu | 30 | 2024-11-01 | 2024-10-23 |
| Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer Eribulin, Bevacizumab - Breast Neoplasms, Neoplasm Metastasis | Phase 2 | Unknown | Wang Jiayu | 60 | 2024-08-01 | 2024-08-06 |
Breast Neoplasms (1) · Neoplasm Metastasis (1)
Bevacizumab (1) · Vinorelbine (1) · eribulin (1) · liposomal doxorubicin (1)
China (1)